Venture capital for

Life Sciences

We are a life sciences investment firm partnering with industry leaders to build game-changing medicines and technologies with a focus on novel therapeutics for unmet medical needs.

Founded in 2011,
venBio’s venture funds comprise nearly

$ 0.1 billion
in committed capital
approved drugs

that Matter

We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes intellectual property (IP), chemistry, manufacturing (CMC), and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.

Our mission

We seek out teams who are developing treatments that will have a meaningful impact on patient care. Our mission is to put our companies in the best possible position to succeed, by helping teams think through the best development plan to bring these therapies to patients.

Latest news

Mar 6, 2024

Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction

Read more

Mar 5, 2024

Q&A: Ken Song details RayzeBio’s path from Series A to IPO in 3 years

Read more

Feb 8, 2024

Attralus Closes $56 Million Financing

Read more